NARA Discovery
Article Details
← Back to Search Results
Journal Article

Serum Neurofilament Light Levels in Patients with Cerebrotendinous Xanthomatosis: a Pilot Study

Antonio Edvan Camelo-Filho; Pedro Lucas Grangeiro Sá Barreto Lima; Rodrigo Fagundes da Rosa; Oliver R Miyajima; Matheus Henrique Brustolim Marcucci; Stephanie Suzanne de Oliveira Scott; Luis Edmundo Teixeira de Arruda Furtado; Annyta F Frota; Michelle V R Soares; Danielle S Macedo; André Pessoa; Paulo R Nóbrega; Pedro Braga-Neto
The Cerebellum · Vol. 25, Issue 3 · 2026

Abstract

Introduction: Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive disorder caused by pathogenic variants in CYP27A1 , leading to cholestanol accumulation and progressive neurological dysfunction. Neurofilament light chain (NfL) is a biomarker of neuroaxonal injury in several hereditary ataxias, but its role in CTX has not been investigated. We aimed to determine whether serum NfL is elevated in CTX and whether it correlates with clinical severity. Methods: Five genetically confirmed CTX patients and five age-, sex-, and body mass index–matched healthy controls were evaluated. Clinical severity was assessed using the Scale for the Assessment and Rating of Ataxia (SARA). Serum NfL concentrations were measured using single-molecule array technology. Group comparisons were performed using the Mann–Whitney U test, and associations were assessed using Spearman’s correlation coefficient. Results: Serum NfL levels were significantly higher in CTX patients than in controls (median 14.63 pg/mL [interquartile range 5.10–18.17] vs. 2.90 pg/mL [2.52–3.56]; p = 0.008). Within the CTX group, NfL levels showed a strong positive correlation with SARA scores (Spearman's ρ = 0.90, p = 0.037), indicating higher NfL levels in patients with greater neurological impairment. Conclusion: Serum NfL is elevated in CTX and correlates with ataxia severity, supporting its potential relevance as a marker of neuroaxonal injury in this disorder. Larger longitudinal studies are needed to confirm these preliminary findings and clarify the role of NfL in disease monitoring.

Bibliographic Information

JournalThe Cerebellum
PublisherSpringer
Publication Date2026-04-17
Publication Year2026
Volume25
Issue3
Document TypeJournal Article
eISSN1473-4230
DOI10.1007/s12311-026-01993-5

Access Information

NARA Access Coverage2002-01-01~Current
Journal Homepagehttps://www.springer.com/journal/12311
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.